UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K/A
(Amendment No. 1)
(Mark One)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2000
OR
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _________ to _________
Commission File Number: 0-27488
INCYTE GENOMICS, INC.
(Formerly Incyte Pharmaceuticals, Inc.)
(Exact name of registrant as specified in its charter)
Delaware 94-3136539
(State of other jurisdiction of incorporation or organization) (IRS Employer Identification No.)
3160 Porter Drive, Palo Alto, California 94304 (650) 855-0555
(Address of principal executives offices) (Registrant's telephone number, including area code)
Securities registered to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $.001 per share
Series A Participating Preferred Stock Purchase Rights
Indicate by check mark whether the registrant (1) has filed all reports
required by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [X] No [_]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K (Section 229.405 of this chapter) is not contained herein,
and will not be contained, to the best of registrant's knowledge, in definitive
proxy or information statements incorporated by reference in Part III of this
Form 10-K or any amendment to this Form 10-K. [_]
The aggregate market value of Common Stock held by non-affiliates (based
upon the closing sale price on the Nasdaq National Market on February 28, 2001)
was approximately $1,105,595,000.
As of February 28, 2001, there were 65,760,321 shares of Common Stock,
$.001 per share par value, outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Items 10 (as to directors and Section 16(a) Beneficial Ownership Reporting
Compliance), 11 and 12 of Part III incorporate by reference information from the
registrant's proxy statement to be filed with the Securities and Exchange
Commission in connection with the solicitation of proxies for the registrant's
2001 Annual Meeting of Stockholders to be held on June 5, 2001.
PART III
Item 13. Certain Relationships and Related Transactions
In March 2001, Incyte Genomics, Inc. (the "Company") entered into a LifeSeq
Collaboration Agreement, Patent License Agreement, Collaboration and Technology
Transfer Agreement and Proteome BioKnowledge Library License Agreement with
Genomic Health, Inc. ("Genomic Health"). Under these agreements, Genomic Health
obtained access to the Company's LifeSeq Gold database and BioKnowledge Library
and received licenses to certain of the Company's intellectual property. Amounts
Genomic Health will pay the Company under these agreements are similar to those
paid to the Company under agreements between the Company and unrelated third
party customers. The Company received rights to certain intellectual property
that Genomic Health may, in the future, develop. At the same time, the Company
purchased shares of Series C Preferred Stock of Genomic Health for an aggregate
purchase price of $5.0 million which, together with shares of Series A Preferred
Stock purchased in November 2000 for an aggregate purchase price of $1.0
million, results in the Company owning approximately 10.9% of the outstanding
capital stock of Genomic Health. Under certain circumstances and if Genomic
Health so elects, the Company has agreed to purchase in a future offering of
Genomic Health's capital stock an aggregate of $5.0 million of the shares being
sold in that offering. Randal W. Scott, Chairman of the Board of the Company, is
Chairman of the Board, President and Chief Executive Officer of Genomic Health
and owns more than 10% of the outstanding capital stock of Genomic Health.
Persons and entities associated with Four Partners, a significant stockholder of
the Company, own approximately 12.7% of the outstanding capital stock of Genomic
Health.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Company has duly caused this Amendment to Report to be
signed on its behalf by the undersigned, thereunto duly authorized.
INCYTE GENOMICS, INC.
Date: May 8, 2001
By: /s/ E. Lee Bendekgey
---------------------------------------------
E. Lee Bendekgey
Executive Vice President and General Counsel
EXHIBIT INDEX
Exhibit
Number Description of Document
------- -----------------------
3(i)(a) Restated Certificate of Incorporation, as amended.
3(i)(b) Certificate of Designation of Series A Participating Preferred Stock, (incorporated by reference to the
Company's Annual Report on 10-K for the year ended December 31, 1998).
3(ii) Bylaws of the Company, as amended (incorporated by reference to Exhibit 4.2 to the Company's Registration
Statement on Form S-3 (File No. 333-31307)).
4.1 Form of Common Stock Certificate (incorporated by reference to the exhibit of the same number to the Company's
Registration Statement on Form S-1 (File No. 33-68138)).
4.2 Rights Agreement dated as of September 25, 1998 between the Company and Chase Mellon Shareholder Services,
L.L.C., which includes as Exhibit B, the rights certificate (incorporated by reference to Exhibit 4.1 to the
Company's Registration Statement on Form 8-A filed September 30, 1998).
4.3 Indenture dated as of February 4, 2000 between the Company and State Street Bank and Trust Company of
California, N.A., as trustee (incorporated by reference to the exhibit of the same number to the Company's
Annual Report on Form 10-K for the year ended December 31, 1999).
10.1# 1991 Stock Plan of Incyte Pharmaceuticals, Inc., as amended and restated (the "Plan") (incorporated by reference
to Exhibit 10.18 to the Company's Registration Statement on Form S-8 (File No. 333-83291)).
10.2# Form of Incentive Stock Option Agreement under the Plan (incorporated by reference to the exhibit of the same
number to the Company's Registration Statement on Form S-1 (File No. 33-68138)).
10.3# Form of Nonstatutory Stock Option Agreement under the Plan (incorporated by reference to the exhibit of the same
number to the Company's Registration Statement on Form S-1 (File No. 33-68138)).
10.4# Amended and Restated 1993 Directors' Stock Option Plan of Incyte Pharmaceuticals, Inc. (incorporated by
reference to the exhibit of the same number to the Company's Annual Report on Form 10-K for the year ended
December 31, 1997).
10.5# Form of Indemnity Agreement between the Company and its directors and officers (incorporated by reference to
Exhibit 10.5 to the Company's Registration Statement on Form S-1 (File No. 33-68138)).
10.6 Lease Agreement dated December 8, 1994 between the Company and Matadero Creek (incorporated by reference to
Exhibit 10.16 to the Company's Annual Report on Form 10-K for the year ended December 31, 1994).
10.9 Stock Purchase Agreement dated as of June 22, 1994 between the Company and Pfizer Inc (incorporated by reference
to Exhibit B to the Company's Current Report on Form 8-K dated June 23, 1994).
10.10 Registration Rights Agreement dated as of June 22, 1994 between the Company and Pfizer Inc (incorporated by
reference to Exhibit C to the Company's Current Report on Form 8-K dated June 23, 1994).
10.11 Stock Purchase Agreement dated as of November 30, 1994 between the Company and The Upjohn Company (incorporated
by reference to Exhibit B to the Company's Current Report on Form 8-K dated November 30, 1994, as amended by
Form 8-K/A filed with the Commission on March 27, 1995).
10.12 Registration Rights Agreement dated as of November 30, 1994 between the Company and The Upjohn Company
(incorporated by reference to Exhibit C to the Company's Current Report on Form 8-K dated November 30, 1994).
Exhibit
Number Description of Document
------- -----------------------
10.13 Registration Rights Agreement dated as of February 4, 2000 among the Company and Deutsche Bank Securities Inc.
and Warburg Dillon Read LLC (incorporated by reference to the exhibit of the same number to the Company's Annual
Report on Form 10-K for the year ended December 31, 1999).
10.14 Lease Agreement dated June 19, 1997 between the Company and The Board of Trustees of the Leland Stanford Junior
University (incorporated by reference to the exhibit of the same number to the Company's Annual Report on Form
10-K for the year ended December 31, 1999).
10.15# 1997 Employee Stock Purchase Plan of Incyte Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.1 to
the Company's Registration Statement on Form S-8 (File No. 333-31409)).
10.16# 1998 Amendment to the 1997 Employee Stock Purchase Plan of Incyte Pharmaceuticals, Inc. (incorporated by
reference to Exhibit 99 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 1998).
10.17+ Master Strategic Relationship Agreement dated as of September 2, 1997 between SmithKline Beecham Corporation,
Incyte Pharmaceuticals, Inc. and diaDexus, LLC (incorporated by reference to Exhibit 10.18 to the Company's
Quarterly Report on Form 10-Q/A for the quarter ended September 30, 1997).
10.18# 1996 Synteni, Inc. Equity Incentive Stock Plan (incorporated by reference to Exhibit 10.19 to the Company's
Registration Statement on Form S-8 (File No. 333-46639)).
10.19# The Hexagen Limited Unapproved Company Share Option Plan 1996, as amended (incorporated by reference to Exhibit
10.1 to the Company's Registration Statement on Form S-8 (File No. 333-67691)).
10.20 Stock Purchase Agreement dated as February 24, 2000 between the Company and the investors named therein
(incorporated by reference to the exhibit of the same number to the Company's Annual Report on Form 10-K for the
year ended December 31, 1999).
10.21 Registration Rights Agreement, dated as of December 28, 2000, by and among the Company and the Stockholders of
Proteome, Inc. (incorporated by reference to Exhibit 99.1 to the Company's Current Report on Form 8-K filed
January 10, 2001).
10.22# 1998 Employee, Director and Consultant Stock Option Plan of Proteome, Inc., as amended (incorporated by
reference to Exhibit 99.1 to the Company's Registration Statement on Form S-8 filed January 29, 2001 (File No.
333-54496)).
21.1 Subsidiaries of the Company.
23.1 Consent of Ernst & Young LLP, Independent Auditors.
23.2 Consent of PricewaterhouseCoopers LLP, Independent Accountants.
24.1 Power of Attorney.
---------------
+ Confidential treatment has been granted with respect to certain portions of
these agreements.
# Indicates management contract or compensatory plan or arrangement.
Copies of above exhibits not contained herein are available to any
stockholder upon written request to: Investor Relations, Incyte Genomics, Inc.,
3160 Porter Drive, Palo Alto, CA 94034.